ABIG X JD LYMON PRESS RELEASE
ABIG Health and JD Lymon Group Form Strategic Affiliation to Guide Medical Device Innovators From Clearance to Adoption
Medical device and health technology companies gain one coordinated team for regulatory, reimbursement, market access and commercialization strategy across the total product lifecycle.
WASHINGTON & MINNEAPOLIS — NOV. 2, 2026
ABIG Health and JD Lymon Group today announced a strategic affiliation joining two teams of senior healthcare executives to support medical device and health technology innovators across the total product lifecycle.
Early-stage innovators rarely stall on technology. More often, they stall on fragmented advice. Regulatory and reimbursement guidance frequently comes from separate firms that never compare notes, and a decision made for seeking authorization from the U.S. Food and Drug Administration (FDA), such as a trial design, the regulatory pathway chosen, an endpoint or an indication, can weaken the coding, coverage and adoption case later. Multiple contracts and onboarding cycles delay the start of work, and scarce capital goes to coordinating vendors and redoing analyses.
The affiliation is designed to remove that friction by combining complementary strengths. Now, our clients can access the expertise of both firms, addressing issues across the entirety of the product lifecycle all the way to adoption:
01
Clinical scenario and market strategy: defining the clinical use case and target market up front
02
Evidence planning: designing studies that serve FDA, CMS, commercial payers and clinicians together
03
Regulatory strategy: FDA pathway decisions tested against their impact on reimbursement
04
Reimbursement: coding, coverage and payment strategy
05
Market access and launch: payer engagement, value story and commercialization
06
Adoption, engagement and growth: clinician uptake and business strategy
"Companies stall when advice arrives in pieces and nobody owns the whole pathway," said Adam Brown, MD, MBA, Managing Partner at ABIG Health. "ABIG Health and JD Lymon are two teams that inform one strategy and one plan, so the decisions a company makes for FDA are already working for payers, clinicians and investors."
"Our clients have asked for a partner who can see around corners," said Jolayne Devers, Partner and Founder at JD Lymon Group. "Bringing JD Lymon's expertise in commercial payer coverage, coding and payment together with ABIG Health's clinical and regulatory leadership gives them one coordinated team."
"FDA authorization is not coverage," said Steven Farmer, MD, PhD, Senior Partner at ABIG Health and former Chief Strategy Officer for coverage determinations at CMS. "Too many promising technologies reach the market without the evidence payers need to say yes. Planning for coverage from the first study design is the most capital-efficient way to get a device to the patients who need it."
"For an emerging company, every month and every dollar matters," said John McInnes, MD, JD, Partner at JD Lymon Group. "Working as one team means our clients spend less time managing vendors and more time moving toward adoption."
ABOUT ABIG HEALTH
Transforming healthcare, one BIG idea at a time.
ABIG Health is a strategic commercialization partner that helps health tech, digital health, and MedTech companies move from a validated product to real-world revenue in the U.S. market by navigating FDA pathways, CMS and payer reimbursement, clinical feasibility, and go-to-market strategy. Learn more at www.abighealth.com.
ABIG Health’s leadership:
Steven Farmer, MD, PhD, Senior Partner, former CMS Chief Strategy Officer for coverage determinations.
Adam Brown, MD, MBA, Founder and Managing Partner, is a physician, healthcare executive and business school professor who previously served as president of one of the largest emergency medicine practices in the U.S. and is a professor of healthcare strategy at UNC Kenan-Flagler Business School.
ABOUT JD LYMON GROUP
Connecting the Dots of Market Access
JD Lymon Group is a specialized market access consulting firm serving medical technology and biopharmaceutical companies, with deep expertise in commercial payer coverage, coding and payment. Its partners bring more than 125 years of combined medtech experience across industry, payers and government. Learn more at www.jdlymon.com.
JD Lymon Group's five partners:
Jolayne Devers, MBA, CPC, Partner and Founder, has more than 35 years of experience across medical device companies, commercial payers and providers, and has secured CPT, ICD-10 and HCPCS codes and Medicare payment mechanisms for emerging technologies.
Carla Monacelli, Partner and Founder, brings more than 35 years in reimbursement, healthcare policy and government relations, including senior market access roles at Nevro, LivaNova and Allergan.
Mark Domyahn, MBA, Partner, has more than 25 years in medical technology reimbursement and health economics, with leadership roles at Medtronic, CardioMEMS and Zimmer.
John McInnes, MD, JD, Partner, is a board-certified ophthalmologist and attorney who served as a division director at CMS and as counsel at Arnold & Porter.
Amanda Cassidy, MPP, Partner, is a health policy and government affairs specialist and former CMS official who also served as a health policy adviser at Arnold & Porter.